This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Article
  2. Source: Campus Sanofi
  3. 16 Sept 2024
3 min

The impact of exacerbations in COPD

Author: Sanofi Editorial Team

   
light bulb with lungs inside on red background

Dupixent (dupilumab) Prescribing Information (GB only)

COPD exacerbation risk has been shown to accelerate after each exacerbation.2,a 

Exacerbation risk accelerates after each exacerbation2

*Severe exacerbations were defined as those which resulted in hospitalisation with a primary discharge diagnosis of COPD2

Despite triple inhaled therapyc, many patients remain symptomatic as defined by persistent symptoms and exacerbations.2

COPD exacerbations may lead to an accelerated rate of decline in lung function3,d

  • Rate of FEV1 decline nearly double3

  • Lung function decline may occur after only one COPD exacerbation3

aBased on data from a large population-based cohort of 73,106 Canadian patients (mean age 75 years) who were hospitalised for the first time because of a severe exacerbation of COPD (1990-2005, followed until death or March 31, 2007). The hazard functions of successive hospitalised COPD exacerbations and all-cause mortality over time were estimated, and HRs adjusted for age, sex, calendar time and comorbidity. 2
bAdjusted for age, sex, calendar time, and the modified Chronic Disease Score.2
cOr double inhaled therapy if ICS is contraindicated.4
dFEV1 decline after a single moderate-to-severe exacerbation. Based on a retrospective analysis of data from 586 patients with moderate-to-severe COPD.3 

aHR, adjusted hazard ratio; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; QoL, quality of life 

References
  1. Halpin DMG, Dransfield MT, Han MK, et al. The effect of exacerbation history on outcomes in the IMPACT trial. Eur Respir J. 2020;55:1901921.
  2. Suissa S, Dell'Anniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67:957-963.
  3. Halpin DMG, Decramer M, Celli BR, et al. Effect of a single exacerbation on decline in lung function in COPD. Respir Med. 2017;128:85-91.
  4. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2024 report). Available at https://goldcopd.org/2024-gold-report/ Accessed 23/07/2024

MAT-XU-2402874 (v1.0) Date of Preparation: September 2024